Regenxbio Stock Buy Hold or Sell Recommendation
| RGNX Stock | USD 7.37 0.22 3.08% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Regenxbio is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Regenxbio given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Regenxbio, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Regenxbio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide. In addition, we conduct extensive research on individual companies such as Regenxbio and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Regenxbio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Regenxbio |
Execute Regenxbio Buy or Sell Advice
The Regenxbio recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Regenxbio. Macroaxis does not own or have any residual interests in Regenxbio or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Regenxbio's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Regenxbio Trading Alerts and Improvement Suggestions
| Regenxbio generated a negative expected return over the last 90 days | |
| Regenxbio has high historical volatility and very poor performance | |
| Regenxbio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 90.24 M. Net Loss for the year was (263.49 M) with loss before overhead, payroll, taxes, and interest of (164.98 M). | |
| Regenxbio currently holds about 402.96 M in cash with (218.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Regenxbio has a poor financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from kalkinemedia.com: Viral Vector Manufacturing Market to Grow at CAGR of 19.22 percent CAGR by 2030 Report by DelveInsight |
Regenxbio Returns Distribution Density
The distribution of Regenxbio's historical returns is an attempt to chart the uncertainty of Regenxbio's future price movements. The chart of the probability distribution of Regenxbio daily returns describes the distribution of returns around its average expected value. We use Regenxbio price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Regenxbio returns is essential to provide solid investment advice for Regenxbio.
| Mean Return | -0.36 | Value At Risk | -8.26 | Potential Upside | 6.35 | Standard Deviation | 5.25 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Regenxbio historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Regenxbio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Regenxbio, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Regenxbio back and forth among themselves.
| Shares | Aquilo Capital Management, Llc | 2024-09-30 | 930.7 K | Goldman Sachs Group Inc | 2024-09-30 | 743.4 K | Adar1 Capital Management Llc | 2024-09-30 | 569 K | Assenagon Asset Management Sa | 2024-09-30 | 559.9 K | Northern Trust Corp | 2024-09-30 | 488 K | Bank Of America Corp | 2024-09-30 | 446.2 K | Charles Schwab Investment Management Inc | 2024-09-30 | 417.7 K | Sonic Gp Llc | 2024-09-30 | 403.1 K | Rtw Investments, Llc | 2024-09-30 | 350 K | Blackrock Inc | 2024-09-30 | 8.8 M | Redmile Group, Llc | 2024-09-30 | 4.9 M |
Regenxbio Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 5.3M | 2.4M | 17.9M | 29.3M | 33.7M | 35.4M | |
| Change In Cash | 268.9M | 7.5M | (248.3M) | (62.4M) | (56.2M) | (53.4M) | |
| Free Cash Flow | (80.9M) | 134.7M | (238.2M) | (228.4M) | (205.5M) | (195.3M) | |
| Other Non Cash Items | (1.2M) | 4.4M | 5.2M | (1.6M) | (1.9M) | (1.8M) | |
| Capital Expenditures | 26.9M | 84.2M | 30.7M | 10.0M | 11.5M | 19.3M | |
| Net Income | (111.3M) | 127.8M | (280.3M) | (263.5M) | (237.1M) | (225.3M) | |
| End Period Cash Flow | 339.8M | 347.2M | 99.0M | 36.6M | 42.0M | 39.9M | |
| Investments | 147.3M | (322.5M) | (11.9M) | 183.7M | 211.2M | 221.8M | |
| Depreciation | 8.4M | 9.6M | 12.9M | 17.3M | 19.9M | 20.9M | |
| Change To Netincome | 21.1M | 40.6M | 41.3M | 45.9M | 52.8M | 55.5M | |
| Change Receivables | (16.8M) | (8.6M) | (9.9M) | 14.1M | 16.2M | 17.0M |
Regenxbio Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Regenxbio or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Regenxbio's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Regenxbio stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.38 | |
β | Beta against Dow Jones | 0.64 | |
σ | Overall volatility | 5.28 | |
Ir | Information ratio | -0.07 |
Regenxbio Volatility Alert
Regenxbio exhibits very low volatility with skewness of 0.42 and kurtosis of 1.7. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Regenxbio's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Regenxbio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Regenxbio Fundamentals Vs Peers
Comparing Regenxbio's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Regenxbio's direct or indirect competition across all of the common fundamentals between Regenxbio and the related equities. This way, we can detect undervalued stocks with similar characteristics as Regenxbio or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Regenxbio's fundamental indicators could also be used in its relative valuation, which is a method of valuing Regenxbio by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Regenxbio to competition |
| Fundamentals | Regenxbio | Peer Average |
| Return On Equity | -0.72 | -0.31 |
| Return On Asset | -0.26 | -0.14 |
| Profit Margin | (2.83) % | (1.27) % |
| Operating Margin | (2.57) % | (5.51) % |
| Current Valuation | 182.85 M | 16.62 B |
| Shares Outstanding | 49.55 M | 571.82 M |
| Shares Owned By Insiders | 7.57 % | 10.09 % |
| Shares Owned By Institutions | 92.72 % | 39.21 % |
| Number Of Shares Shorted | 6.04 M | 4.71 M |
| Price To Earning | 12.80 X | 28.72 X |
| Price To Book | 1.18 X | 9.51 X |
| Price To Sales | 4.33 X | 11.42 X |
| Revenue | 90.24 M | 9.43 B |
| Gross Profit | (164.98 M) | 27.38 B |
| EBITDA | (239.46 M) | 3.9 B |
| Net Income | (263.49 M) | 570.98 M |
| Cash And Equivalents | 402.96 M | 2.7 B |
| Cash Per Share | 9.32 X | 5.01 X |
| Total Debt | 89.29 M | 5.32 B |
| Debt To Equity | 0.14 % | 48.70 % |
| Current Ratio | 4.06 X | 2.16 X |
| Book Value Per Share | 6.08 X | 1.93 K |
| Cash Flow From Operations | (218.41 M) | 971.22 M |
| Short Ratio | 3.28 X | 4.00 X |
| Earnings Per Share | (5.16) X | 3.12 X |
| Price To Earnings To Growth | 0.26 X | 4.89 X |
| Target Price | 36.91 | |
| Number Of Employees | 344 | 18.84 K |
| Beta | 1.23 | -0.15 |
| Market Capitalization | 365.15 M | 19.03 B |
| Total Asset | 573.97 M | 29.47 B |
| Retained Earnings | (705.05 M) | 9.33 B |
| Working Capital | 204.7 M | 1.48 B |
Note: Disposition of 11395 shares by Christmas Patrick J. of Regenxbio at 7.73 subject to Rule 16b-3 [view details]
Regenxbio Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Regenxbio . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Regenxbio Buy or Sell Advice
When is the right time to buy or sell Regenxbio? Buying financial instruments such as Regenxbio Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Regenxbio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Convertibles Funds Thematic Idea Now
Convertibles Funds
Funds or Etfs that invest in debt that is expected to be converted into a predetermined amount of the company equity at some future date. The Convertibles Funds theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Convertibles Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Regenxbio Stock Analysis
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.